PharmaTalkRadio

PharmaTalkRadio

By Pharma Talk RadioScience
Download on the App Store

PharmaTalkRadio episodes

  • Mechanisms of Immune Evasion Mediated by Hypoxia- Inducible Factors
    In this session, first recorded at the 2022 IO360° Summit, Dr Semenza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include:
    Regions of intratumoral hypoxia are a common feature of advanced cancersHypoxia-inducible factors increase the expression of multiple proteins that mediate immune evasionHIF inhibitors stimulate anti-tumor immunity and improve the response to immune checkpoint blockade
    Gregg Semenza, MD, PhD, Director, Vascular Program, Institute for Cell Engineering and Professor of Genetic Medicine, Johns Hopkins University School of Medicine
    Learn more about the IO360° Summit at www.io360summit.com
    23 min
  • Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Pri
    Neoadjuvant (pre-surgical) immune checkpoint blockade may prevent cancer relapse and progression.This treatment approach is now FDA-approved for resectable triple-negative breast cancer, and hundreds of clinical trials in other cancers are ongoing.Surgical resection specimens collected after several weeks of neoadjuvant ICB offer vast opportunities for predictive biomarker discovery and understanding ICB response/resistance.
    Suzanne Topalian, MD, Associate Director / Professor of Surgery, Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University
    Learn more about the IO360° Summit at www.io360summit.com
    27 min
  • Panel: Targeted Radiotherapy and the Impact on IO
    What is the impact of targeted radiotherapy on the immune system?What are the implications for combination IO?Current approaches and future direction
    Moderated by:
    Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen
    Panelists:
    Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , NovartisMatthew Silva, PhD, CEO , InvicroOhad Ilovich, PhD, Senior Director, Translational Sciences, Curie Therapeutics
    Learn more about the IO360° Summit at www.io360summit.com
    31 min
  • KEYNOTE FIRESIDE CHAT with Dr Robert Langer and Dr Ester Caffarel-Salvador
    In this podcast, you will hear a keynote fireside discussion with Dr Robert Langer, MIT, and Dr Ester Caffarel-Salvador, Chiesi USA, from the 2022 PODD Conference regarding current projects in the Langer Lab, how COVID affected the lab’s dynamics and collaborations, challenges in the drug delivery space, and exciting technologies in the pipeline, 
    To learn more about the PODD Conference, please visit PODDConference.com.
    36 min
  • Panel: Role of China in the BD Process
    This panel, first recorded at the 2021 Immuno-Oncology 360° Summit, will bring together chinese biotechs to share how they are partnering with additional IO companies to advance cancer treatments for patients. This will include partnering strategies and decision making. To learn more about the IO360° Summit visit, www.io360summit.com
    31 min
  • Gaining “Hard-to-Reach” Patients’ Input During the Global COVID Pandemic
    In this session, GSK shares how they delivered on patient and caregiver engagements, especially with communities experiencing the highest COVID burden. They gained insights on study designs, educational pieces and captured patient experiences to enhance HCP/public COVID awareness. GSK will discuss:
    Value of COVID engagements
    Novel approaches and mechanisms for finding patients who don’t belong to an organized patient community
    Overcoming challenges
    How this initiative could be modeled to help find future patients when the pathway is not clear
    Patient Perspectives-In their own words
    Susan Burriss, Patient Engagement Lead, GSK
    Learn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
    19 min
  • How Janssen is Collaboratively Working with Patients and Sites to Advance DCTs
    In this session, Janssen shares how they are collaboratively working with patients and sites to advance DCTs and will
    share engagement methodologies, what they have learned from the perspective of participants and sites, and the direction
    this has taken them in DCTs.
    Alyson Gregg, Director Patient Insights, GMA Commercial Operations, Janssen
    Morgan Wooten, Investigator & Patient Engagement Program Team Leader, Janssen
    Learn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
    18 min
  • How Merck is Partnering with Communities to Support Clinical Research
    Merck’s iLab53 (a modular 39-foot mobile unit) was used to bring clinical research into community settings as an effort to increase clinical trial awareness and engagement.
    More specifically:
    How the iLab53 was created and implemented
    How Merck is continuing to work to help build trust within communities, and provide increased access to clinical research
    Challenges, learnings and successes to date
    How this initiative can be scaled and adapted
    Susan Manoff, MD, MPH, Executive Director, Office of the Chief Patient Officer, Merck
    Kai Bode, Director, Digital Innovation and Patient Strategy, Global Digital Analytics & Technologies Team, Merck
    Learn more about the Patients as Partners in Clinical Research conference at www.patientsaspartners.org
    21 min

About PharmaTalkRadio

From the publisher's feed

PharmaTalkRadio is an internet radio podcast platform organized and supported by the Conference Forum to give easy and free access to industry professionals, patient advocacy and students in medicine…